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Arylamine N-acetyltransferases (NATs) are polymorphic drug-metabolizing enzymes, acetylating arylamine carcinogens and
drugs including hydralazine and sulphonamides. The slow NAT phenotype increases susceptibility to hydralazine and isoniazid
toxicity and to occupational bladder cancer. The two polymorphic human NAT loci show linkage disequilibrium. All
mammalian Nat genes have an intronless open reading frame and non-coding exons. The human gene products NAT1 and
NAT2 have distinct substrate specificities: NAT2 acetylates hydralazine and human NAT1 acetylates p-aminosalicylate (p-AS)
and the folate catabolite para-aminobenzoylglutamate (p-abaglu). Human NAT2 is mainly in liver and gut. Human NAT1 and
its murine homologue are in many adult tissues and in early embryos. Human NAT1 is strongly expressed in oestrogen
receptor-positive breast cancer and may contribute to folate and acetyl CoA homeostasis. NAT enzymes act through a
catalytic triad of Cys, His and Asp with the architecture of the active site-modulating specificity. Polymorphisms may cause
unfolded protein. The C-terminus helps bind acetyl CoA and differs among NATs including prokaryotic homologues. NAT in
Salmonella typhimurium supports carcinogen activation and NAT in mycobacteria metabolizes isoniazid with polymorphism a
minor factor in isoniazid resistance. Importantly, nat is in a gene cluster essential for Mycobacterium tuberculosis survival inside
macrophages. NAT inhibitors are a starting point for novel anti-tuberculosis drugs. Human NAT1-specific inhibitors may act in
biomarker detection in breast cancer and in cancer therapy. NAT inhibitors for co-administration with 5-aminosalicylate (5-AS)
in inflammatory bowel disease has prompted ongoing investigations of azoreductases in gut bacteria which release 5-AS from
prodrugs including balsalazide.
Abbreviations
5-AS, 5-aminosalicylate; ES, embryonic stem; IBD, inflammatory bowel disease; MTP, methyl triazolophthalazine; NAT,
arylamine N-acetyltransferase; p-aba, para-aminobenzoic acid; p-abaglu, para-aminobenzoylglutamate; p-AS,
para-aminosalicylate; SAR, structure activity relationship; SLE, systemic lupus erythematosus; SNP, single nucleotide
polymorphism
Introduction
This review describes studies of the drug-metabolizing enzyme
arylamine N-aetyltransferase (NAT) over a period of some 30
years up to the present day, whichwas presented as the JRVane
Lecture in December 2012. The work includes early pharma-
cogenetic analysis, use of isoenzyme specific antibodies in
Western blotting and immunohistochemistry; transgenic
mice, which may have generated more questions than
answers, large-scale recombinant protein expression for struc-
tural studies and development of isoenzyme specific inhibi-
tors. Isoniazid, the anti-tubercular prodrug, is metabolized by
NAT (Figure 1) and prompted work on NAT in mycobacteria,
stimulating investigations in drug discovery. Recent work on
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azoreductases, which generate arylamines from azo drug pre-
cursors, is also covered. These studies have relied on an enthu-
siastic band of co-investigators and collaborators including
project students and graduate research students (Supporting
Information Table S1). The present review adds to earlier sum-
maries (Sim et al., 2000; 2007; 2008a–c).
NATs came to prominence in identifying acetyl CoA as a
key metabolic intermediate (Lippmann and Kaplan, 1946).
Their role in xenobiotic metabolism has been wide-reaching
for early insight into interindividual differences in the ability
to metabolize drugs (Kalow, 2004; Weber and Hein, 1985 for
reviews). Studies on arylamine N-acetyltransferases (NATs)
were among the earliest examples of pharmacogenetic varia-
tion (Evans et al., 1960) and laid the foundation for under-
standing that different ethnic populations could differ
considerably in drug metabolism (see Jones, 2013) with
important implications for clinical trials (Tam et al., 2000).
NAT polymorphism also has importance in understanding
adverse side effects (see Park et al., 1992).
The corresponding author’s journey in drug metabolism
was triggered by attempts to understand how an environ-
mental factor, the drug, could lead to an adverse reaction.
These studies were carried out firstly in the Pharmacology
Department in South Parks Road in Oxford and subsequently
in the iconic building in Mansfield Road for which the funds
were raised by Prof. David Smith from Squibb. The building
was opened by JR Vane in the summer of 1991 (Figure 2).
Since 2011, the studies have been continued at Kingston
University.
Figure 1
Metabolic reactions catalysed by arylamine N-acetyltransferase. Acetylation reactions from the top show N-acetylation of an arylamine,
p-aminobenzoic acid; N-acetylation of isoniazid; O-acetylation of an arylhydroxylamine and the bottom reaction shows N,O acetyltransfer in a
hydroxamate. The top three reactions use acetyl CoA as a cofactor while the bottom reaction does not. The bottom two reactions are associated
with carcinogenesis. From Sim et al., 2010.
Figure 2
JR Vane at the opening of the Pharmacology Department, Oxford
1991. John Vane is on the right, David Smith, Head of Department,
is in the middle and the head of research of Squibb Pharmaceuticals,
who gave the endowment before the Bristol-Meyers takeover is on
the left.
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Adverse drug reactions
Even in the post-genomic era, identification of an environ-
mental trigger of disease can be very difficult, and therefore,
adverse drug reactions have the advantage that the drug
serves as a readily identifiable environmental factor
(McDowell et al., 2013). I chose to study hydralazine-
induced systemic lupus erythematosus (SLE; Batchelor et al.,
1980). Immune complexes become deposited in capillaries
and in kidney glomeruli with inhibition of the complement
cascade contributing to SLE susceptibility (Walport, 2002 for
review). We showed hydralazine inhibited the solubilization
of immune complexes by blocking complement component
C4, which is polymorphic (Sim et al., 1984), with hydrala-
zine inhibiting the C4A type more than the C4B type (Sim
and Law, 1985). Immune system polymorphisms had a role
in predisposition to hydralazine-induced SLE (Mitchell et al.,
1987; 1989; Mitchell and Sim, 1989) but the most important
polymorphism was the ability to metabolize hydralazine
(Drayer and Reidenberg, 1977). Hydralazine is acetylated
polymorphically to produce cyclized methyl triazoloph-
thalazine (MTP; Timbrell et al., 1980). When complement
component C4 is activated a thiol ester is exposed, which
binds covalently to adjacent immune complex (Sim et al.,
1981) leading to solubilization. Hydralazine, but not its
acetylated metabolite MTP, blocked covalent binding of
complement component C4 (Figure 3; Sim et al., 1984). In
the process, hydralazine becomes bound to C4 (Sim and
Law, 1985).
The metabolism of hydralazine has been investigated
extensively and recent structural studies with recom-
binant NAT protein have demonstrated the mechanisms
of the cyclization reaction (Figure 4; Abuhammad et al.,
2010).
NAT and pharmacogenetics
In the 1960’s, it had been established that there was poly-
morphism in isoniazid inactivation by human NAT activity
(Evans et al., 1960). This is the classic textbook pattern of
distribution into fast and slow acetylators (Figure 5). Fast and
slow acetylators were classified with several drugs including
isoniazid, hydralazine and sulphamethazine (see Weber and
Hein, 1985). It was also identified that ethnic populations
varied such that in Orientals, there were approximately 15%
slow acetylators while in the Caucasian population, around
50% were slow acetylators (Harris et al., 1958; Sim and
Hickman, 1991). The slow acetylator phenotype was, in early
studies, found to be more prevalent in isoniazid-induced tox-
icity as well as in hydralazine-induced lupus (Woosley et al.,
1978). More recent studies have demonstrated that isoniazid-
induced hepatotoxicity have also been associated with the
slow acetylator type (Gupta et al., 2013).
In a landmark study, it was also shown that slow acetyla-
tion was a major predisposing factor in industrial bladder
cancer (Cartwright et al., 1982) where bladder cancer had been
known since the late 19th century to be linked to exposure to
aniline dyes (Rehn, 1895; see Dietrich and Dietrich, 2001).
Some drugs were identified, which were metabolized by
acetylation but there did not appear to be the same distribu-
tion among individuals into fast and slow acetylators. These
drugs included para-aminosalicylate (p-AS) and the com-
pound para-aminobenzoic acid (p-aba). These drugs were
referred to as monomorphic as opposed to the drugs like
procainamide, isoniazid and hydralazine, which were known
as polymorphic (see Weber and Hein, 1985).
Figure 3
Hydralazine inhibits binding of complement component C4. Radi-
olabelled C4 was activated by a model for immune complexes (C1s
bound to Sepharose) and the inhibition of binding was compared
using hydralazine or its acetylated metabolite, methyltriazoloph-
thalazine synthesized by EW Gill. From Sim et al. (1984).
Figure 4
Two possible routes of acetylation of hydralazine. From the crystal
structure and the different tautommers and ionization states it is
proposed that hydralazine may also be acetylated initially at the N in
the heterocyclic ring. In either case, cyclization is proposed to gen-
erate methyltriazolophthalazine. From Abuhammad et al. (2010).
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An inkling of the cause behind two different classes of
substrate came from some outstanding experiments by Jenne
(1965). Two enzymic activities in human liver homogenates
were separated by ion exchange chromatography and the
profile differed when activity was measured with p-AS and
with sulphamethazine. Some 10–15 years later using molecu-
lar biology, two different human NAT isoenzymes (Blum
et al., 1990; Deguchi et al., 1990) were found, now known as
human NAT1 and NAT2 each catalysing the acetylation of
arylamines using acetyl CoA as the acetyl donor. Only NAT2
catalyses the acetylation of hydralazine, procainamide and
isoniazid while p-AS is only acetylated by human NAT1
(Figure 6). As more versatile assay methods have become
available (Brooke et al., 2003a), it has been possible to estab-
lish an easy method of comparing the substrate specificities
of a range of different NAT enzymes (Figure 6) and this dem-
onstrates clearly that the human NAT enzymes have different
but overlapping substrate specificity profiles (Figure 6).
Finding two functional human NAT proteins did not
solve the basis of polymorphism in metabolism but early
cloning experiments provided the clue to the polymorphism
in metabolism of drugs by human NAT2. In the pre-PCR,
pre-whole genomic age and specific polynucleotide probes to
screen DNA libraries were identified through translation of
protein sequence. We had previously chosen to purify NAT
from mouse liver (Watson et al., 1990) but rabbit was a much
better choice (Andres et al., 1987; 1988; Sasaki et al., 1991).
Partial protein sequence from pure NAT from rabbit liver NAT
was published by Andres, an inventive contributor to the
NAT field (Andres et al., 1987). This paper appeared when I
was on maternity leave.
Fortuitously, using the sequence information from rabbit,
both a Japanese and a European group chose to clone human
NAT genes (Blum et al., 1990; Ohsako and Deguchi, 1990).
These studies show how the accumulation of data serves to
solve apparently intractable problems. The differences, which
had been observed in the distribution of fast and slow acety-
lation in Oriental and Caucasian populations, were reflected
in the DNA clones described in these two studies. Both groups
found two different genes, NAT1 and NAT2, (Blum et al.,
1990; Ohsako and Deguchi, 1990). Point mutations in the
human NAT2 gene leading to poor acetylation (Deguchi et al.,
1990; Blum et al., 1991) were found but the point mutations
in the Japanese group were different from those in Caucasians
(Deguchi et al., 1990; Blum et al., 1991).
Soon afterwards, we developed a restriction fragment
length polymorphism PCR genotyping method for NAT2
(Hickman and Sim, 1991; Hickman et al., 1992). Now
microarray-based single nucleotide polymorphism (SNP)
analyses (Hein and Doll, 2012) and cheap and comprehensive
sequencing across the chromosomal region are used (Patin
et al., 2006a,b; Sabbagh et al., 2011; Tilak et al., 2013). These
studies have also allowed the establishment of gene frequen-
cies in a wide range of ethnic populations and disease states
(e.g. Garte et al., 2001).
In the initial cloning experiments, the Japanese used
cDNA (Ohsako and Deguchi, 1990) while the Meyer group
used genomic DNA (Blum et al., 1990). The latter studies
identified a third pseudogene, which was not transcribed and
hence was not found in the cDNA library (Blum et al., 1990).
Comparison of the cDNA and genomic DNA clones showed
the open reading frames of each of the NAT1 and NAT2 genes
were intronless. Human NAT1 (Ebisawa and Deguchi, 1991)
has a non-coding exon and we now know there are a series of
upstream non-coding exons in the human NAT1 gene and
that the splicing of these into the proximal region immedi-
ately in front of the coding exon may be tissue specific
(Husain et al., 2004; Boukouvala and Sim, 2005; Barker et al.,
2006; see Minchin et al., 2007).
Human NAT2 also has a non-coding exon spliced in frame
with its single coding exon (Husain et al., 2007; see Sim et al.,
2010). The extended NAT2 gene is much simpler than the
multiple alternative transcripts of human NAT1. The wide
spread tissue expression of human NAT1 (in most tissues
including endocrine tissues, blood cells, neural tissue as well
as gut and liver) compared with the more restricted expres-
sion of human NAT2 (mainly gut and liver) may underlie the
more complex gene organisation (see Minchin et al., 2007).
These genes as well as the human pseudogene are in close
proximity in the genome in the region 8p22 (Hickman et al.,
1994; Franke et al., 1994).
Although in the initial cloning experiments NAT1 was
found to be invariant among individuals, we now know that
human NAT1 also has different alleles (Vatsis and Weber,
1993; Grant et al., 1997; Payton and Sim, 1998). Point muta-
tions in the open reading frame along have been described as
well as alleles with no mutations in the coding exon but there
were insertions and deletions at the 3′ end of the gene (Vatsis
and Weber, 1993). Genotypng NAT1 using PCR-based
methods were more complex than for NAT2 (Smelt et al.,
1998; Pirmohamed et al., 2000; Johnson et al., 2004). Multi-
plex SNP analyses are still used (see Hein, 2009) but genotyp-
ing through sequencing is now the method of choice.
We know there is linkage disequilibrium across the 200kb
region on chromosome 8 in which all three NAT genes are
Figure 5
Isoniazid pharmacokinetics in a population. After Evans et al. (1960).
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Figure 6
Specificity profile of NATs. A range of different NAT enzymes were prepared and their specificity was determined with the same panel of substrates
in each case The specific activity profiles of three eukaryotic NATs and three prokaryotic NATs have been reported. Specific activities are presented
as percent compared with the most active substrate for each enzyme. STNAT, NAT from S. typhimurium; PANAT, NAT from P. aeruginosa; MSNAT,
NAT from M. smegmatis; SMZ, sulfamethazine; PRO, procainamide; 5-AS, 5-aminosalicylic acid; PABA, 4-aminobenzoic acid; 2-AF,
2-aminofluorene; 4-CA, 4-chloroaniline; 4-BA, 4-bromoaniline; 4-IA, 4-iodoaniline; ANS, 4-anisidine; EOA, 4-ethoxyaniline; BOA, 4-butoxyaniline;
HOA, 4-hexyloxyaniline; POA, 4-phenoxyaniline; AMV, 4-aminoveratrole; INH, isoniazid; CBZ, 4-chlorobenzoic hydrazide; HDZ, hydralazine
(Westwood et al., 2006).
BJPNATs: JR Vane lecture 2012
British Journal of Pharmacology (2014) 171 2705–2725 2709
found (Cascorbi et al., 1995; 2001; Smelt et al., 1998) and this
has been exploited in molecular anthropological studies of
population migration and microevolution (Patin et al.,
2006a,b; Sabbagh et al., 2011). In order to understand differ-
ential expression of the two human NATs, we developed
antibodies against the intact proteins, which detect both
NAT1 and NAT2, as they are over 80% identical in sequence.
The C-termini differ sufficiently to use the C-terminal dode-
capeptide to generate a human NAT1-specific antibody,
which has been widely employed (e.g. Butcher et al., 1998;
Adam et al., 2003; Johansson et al., 2012). The anti-NAT2
antibody has not been so successful.
Effects of mutations in human NAT2 and
human NAT1
A series of reviews of the effects of each of the mutations
in human NAT1 and NAT2 has been carried out through
modelling (Rodrigues-Lima and Dupret, 2002; Walraven
et al., 2008; Rajasekaran et al., 2011). A full description
of all NAT1 and NAT2 alleles is to be found on the web
site initially curated by David Hein (http://louisville.edu/
medschool/pharmacology/consensus-human-arylamine-n-
acetyltransferase-gene-nomenclature/) and now hosted at
http://nat.mbg.duth.gr/.
Specific highlights will be covered here.
Most alleles of human NAT1 and NAT2 are haplotypes of
several point mutations with one being a signature mutation,
which alone causes a change such that the resultant protein
shows reduced activity. Wide phenotypic spread in the phar-
macokinetics of isoniazid (Ellard and Gammon, 1976) had
been identified and molecular studies confirmed the earlier
twin studies of (Evans et al., 1960), namely, that slow alleles
of human NAT2 are somatically inherited. While one ‘slow’
allele confers the slow acetylation phenotype, those with two
‘slow’ alleles show a more extreme phenotype (Hickman and
Sim, 1991). Inherent effects of the level of ‘slowness’ con-
ferred by different NAT2 alleles have not been fully explored
(Ruiz et al., 2012).
However alleles fall into two classes, those that cause
unstable protein and those which affect the activity of a
folded protein.
A list of the main mutations that affect amino acids in
human NAT1 and NAT2 are shown in Table 1. The premature
stop codons in human NAT1 are readily understood (Hubbard
et al., 1998; Hughes et al., 1998; Payton and Sim, 1998).
Expressing variant alleles causing amino acid substitu-
tions as recombinant enzymes has identified the effects of
point mutations (Hickman et al., 1995a,b; Walraven et al.,
2008 for review). One amino acid substitution with trypto-
phan substituted for aspartate at position 64 (W64D) occurs
in both NAT1 and NAT2. Two very different elegant studies
(Butcher et al., 2004; Liu et al., 2006) provided the conclusion
that Trp (W) at position 64 results in an unfolded variant,
which accumulates intracellularly in aggresomes for degrada-
tion via ubiquitination through the proteosomal pathway.
An example of a mutation resulting in folded but inactive
protein is the change of aspartate 122 to asparagine (D122N).
Asp122 is an essential part of the charge relay system in the
active site (see below) and asparagine is not effective as has
been confirmed by site-directed mutagenesis (Wang et al.,
2004).
Apparently, healthy individuals with very little NAT1
activity have each been shown to have two defective alleles
(Hughes et al., 1998; Payton and Sim, 1998). It was neverthe-
less shown there was an inverse correlation between NAT1
activity and folate levels in red blood cells (Ward et al., 1992),
which opened up an ongoing debate on the relationship
between NAT1 and folate (see Minchin et al., 2007; Butcher
and Minchin, 2012).
The allele NAT1*10 has had more coverage than any
other: it has no amino acid substitutions within the coding
region – there are deletions and insertions at the 3′ end. In
colon cancer studies, 1*10 was associated with increased
activity (Bell et al., 1995), its effect has been hotly debated for
other tissues where the number of copies of the 1*10 allele
did not correlate with the level of NAT1 activity (Grant et al.,
1997; Payton and Sim, 1998). Effects of NAT1 mutations are
being revisited (Millner et al., 2012a,b) and NAT1*10 remains
an interesting allele. A 1*10 homozygous individual was
identified in a study of patients with Alzheimer’s disease
(Johnson et al., 2004) was identified and NAT1 polymor-
phism, including 1*10, has been implicated in epidemiologi-
cal studies of neural tube defects (Lammer et al., 2004; Jensen
et al., 2005; 2006).
Epigenetic control of NAT gene expression and hence
enzyme activity is yet to be fully explored. CpG islands in the
vicinity of the NAT genes (Matas et al., 1997) and their
murine equivalents (Fakis et al., 2000) indicate methylation
sites and analyses of the upstream spliced region show this is
the case (Kim et al., 2008; Wakefield et al., 2010). Epigenetic
control is an important area for the future.
NATs and cancer
NAT has links with cancer at many levels (Table 2).
Carcinogenesis. Early studies identified that many carcino-
gens were NAT substrates (Bartsch et al., 1973). It was debated
Table 1
Mutations causing amino acid changes in human NAT genes
Mutation
NAT allelic
family
Amino
acid
NAT2 C190T 2*19 Arg64Trp
G191A 2*14 Arg64Gln
T341C 2*5 Ile114Thr
G364A 2*D12 Asp122Asn
A434C 2*17 Gln145Pro
G499A 2*10 Glu167Lys
G590A 2*6 Arg197Gln
A803G 2*12 Lys268Arg
G857A 2*7 Gly286Gln
NAT1 C97T 1*19 Arg33Stop
C190T 1*17 Arg64Trp
C559T 1*15 Arg187Stop
G560A 1*14 Arg187Gln
A752T 1*22 Aso251Val
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whether the drug-metabolizing N-acetyltransferase (see
Weber and Hein, 1985) was the same enzyme as the
carcinogen-activating acetylating activity, which catalysed
N-acetylation, O-acetylation and N,O acetyl transfer in
hydroxamates (Figure 1; King, 1974). The elegant work of
Hanna (Hanna, 1994) in this controversy provided balance
and has further defined the mechanism of protein adduct
formation with human NAT1 (Liu et al., 2009). Recently, N-
and O- acetylation activity in preserved human hepatocytes
has been carried out (Doll et al., 2010).
Cloning the N-hydroxylamino O-acetyltransferase from
Salmonella typhimurium was a major step towards showing
that this activity and NAT in humans were homologues
(Watanabe et al., 1992). Strains of S. typhimurium overexpress-
ing its own nat gene were more sensitive in the Ames test for
carcinogens (Watanabe et al., 1987) and eukaryotic cells
showed increased carcinogenesis when human NATs were
overexpressed (Watanabe et al., 1994).
Bladder cancer. Bladder cancer is a frequently occurring
occupational and smoking-related cancer (Letašiová et al.,
2011 overview). In bladder cancer, there are many links with
NAT. The link between bladder cancer and exposure to NAT
substrates has been known for over a century (Rehn, 1895; see
Dietrich and Dietrich, 2001). The phenotypic link of NAT2
slow acetylation to bladder cancer susceptibility (Cartwright
et al., 1982) has been confirmed by genotyping studies (Risch
et al., 1995) and has been reviewed (Vineis et al., 2001; Hein,
2002). Interestingly, NAT2 is barely expressed in bladder epi-
thelium although NAT1 is. In some bladder tumours, NAT1 is
reduced (Stanley et al., 1996) but no systematic study has
been carried out.
The location of NAT genes in a hot spot on chromosome
8 (Knowles et al., 1993; Spurr et al., 1995; Hubbard et al.,
1997) prompted comparison in bladder tumour and normal
DNA of NAT genes in this unstable region (Stacey et al., 1996;
1997; 1999; Watters et al., 1998). Loss of heterozygosity
(Thygesen et al., 1999) and gene duplication were detected
but whether these changes are causative remains to be estab-
lished. This region was not highlighted in a whole genome
analysis (Kiemenev et al., 2008).
Colorectal cancer. The link between NAT and colorectal
cancer has had a chequered history. The NAT 1*10 allele
association with increased activity stimulated many studies
(Bell et al., 1995). A meta-analysis of 59 studies (Liu et al.,
2012) appears to confirm that there is no link between NAT1
or NAT2 polymorphism and colorectal cancer. Each of these
NAT proteins is detected in the colon and the availability of
specific NAT1 antibodies (Hickman et al., 1998) has clearly
demonstrated staining in the crypts of the colon. This study
showed the ratio of NAT1 to NAT2 among individuals varies
up to 70-fold. The activity of human NAT1 in the gut has
implications also for the treatment of inflammatory bowel
disease (IBD) which is a prediposing factor in colon cancer.
IBD is treated with 5-aminosalicylate (5-AS), which is a sub-
strate for human NAT1 and human NAT2 and this will be
considered below in relation to NAT as a target for novel drug
development.
NAT and breast cancer. From proteomic and genomic studies,
human NAT1 but not NAT2 was found to be overexpressed in
oestrogen receptor-positive female breast cancer (Adam et al.,
2003; see Sim et al., 2008a) and more recently in male breast
cancer (Johansson et al., 2012). NAT2 is only marginally
expressed in any breast tissue.
Understanding NAT1 overexpression in breast cancer and
studies in other endocrine tumours (Butcher et al., 2007;
Butcher and Minchin, 2010) has made use of cell lines
(Wakefield et al., 2008a). The human breast cancer cell line
ZR75 has an extremely high level of human NAT1, which is
neither due to gene duplication nor to a mutant version of
human NAT1.
Studies with siRNA indicate a reduction in contact-
inhibited growth when NAT1 is suppressed (Tiang et al.,
2011; see Butcher and Minchin, 2012). Up-regulation of
Table 2
Relationships between NAT and cancer
Links between NAT and cancer
Carcinogenesis
• Human NAT1 and human NAT2 metabolize arylamine carcinogens, including N-O transfer of an acetyl group in acetylhydroxylamines
to generate N-acetoxyesters
• Strains of S. typhimurium with high NAT activity are more sensitive in Ames test
• Cultured human cells transfected with NAT genes exhibit higher level of mutagenesis
Polymorphism
• Slow acetylator polymorphism in human NAT2 has been linked to bladder cancer but depends on level of exposure
• Polymorphism in human NAT1 and colon cancer has been questioned
Gene expression
• Human NAT1 is overexpressed in oestrogen receptor-positive breast cancer in male and female breast cancer
Cytogenetics
• Human NAT genes encoded in a region of human genome harbouring oncogenes and tumour suppressor genes and show cytogenetic
differences in tumours
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NAT1 in breast cancer has been linked with improved
response to tamoxifen (Bièche et al., 2004) and it has inter-
estingly been observed that human NAT1 (Lu et al., 2001; Lee
et al., 2004) and its mouse equivalent (Kawamura et al., 2008)
is inhibited by tamoxifen and also bisphenol A.
There is no difference in the proportion of fast acetylating
individuals for human NAT2 between a breast cancer and
control group (Webster et al., 1989) and this finding illus-
trates further that the relationship between NAT and breast
cancer involves human NAT1 only.
Human NAT1 and NAT2 in development
In adults, human NAT1 has a much wider tissue distribution
than human NAT2. During development, the difference is
even more marked. In placentae, human NAT1 is found
throughout pregnancy (Smelt et al., 1998; 2000; Upton et al.,
2000) up to term (Derewlany et al., 1994a,b). Foetal tissues
have human NAT1 activity (Pacifici et al., 1986) and NAT1
transcripts were detected at the four-cell stage and in blasto-
cysts (Smelt et al., 2000). Human NAT2 could not be detected
in these studies.
Folate is essential for normal human development and a
link between human NAT1 and folate was hinted at by
the inverse correlation between red blood cell folate and
human NAT1 activity in red cells (Ward et al., 1992). Human
NAT1 was shown to acetylate the folate catabolite para-
aminobenzoylglutamate (p-abaglu) in lymphocytic cell
extracts (Minchin, 1995), in placenta (Upton et al., 2000) and
using recombinant human NAT1 (Ward et al., 1995) but not
human NAT2 (Kawamura et al., 2004).
The physiological role of human NAT1 has raised many
questions (see Minchin et al., 2007) as apparently healthy
adult individuals with two defective human NAT1 alleles
exist (Ward et al., 1992; Hughes et al., 1998; Payton and
Sim, 1998). It was necessary to establish a model system in
order to study further the possible relationship between
folate and NAT and to decipher the role of human NAT1 in
development.
Mouse NATs
Although mouse liver had proved to be a poor choice for
purification of Nat enzymes (Watson et al., 1990), mouse Nats
were most suitable for recombinant protein studies and excel-
lent for investigation of Nat in development. Two mouse
genes, Nat1 and Nat2, which are over 80% identical, were
initially cloned from fast and slow acetylating mouse strains
with each having an intronless open reading frame (Martell
et al., 1991; 1992). An upstream non-coding exon in mouse
Nat2 has also been characterized (Boukouvala et al., 2003; see
Sim et al., 2010).
Mouse Nat1 was identical in the fast and slow strains and
showed specificity for isoniazid while mouse Nat2 catalysed
p-aba acetylation and had a point mutation resulting in
asparagine 99 in the fast strain and isoleucine in the slow
strain resulting in a less stable enzyme (Martell et al., 1992;
De Leon et al., 1995). A third functional mouse gene, Nat3
(Kelly and Sim, 1994), is highly polymorphic and less similar
to the other genes (around 70% identity) but with very low
activity (Fretland et al., 1997; Boukouvala et al., 2002). All
three mouse genes are found in close proximity in the syn-
genic region to chromosome 8p22 where the human NAT
genes are found (Hickman et al., 1994; Fakis et al., 2000).
The naming of mouse Nat2 is historical (Martell et al.,
1991) but perversely has been retained (Hein et al., 2008). It is
the functional equivalent of human NAT1; the substrate
specificity profile of mouse Nat2 is like that of human NAT1
(Kawamura et al., 2008): the C-terminal sequence is the
same as human NAT1 and mouse NAT2 is also recognized
by human NAT1-specific antibodies raised against the
C-terminus. This has allowed mouse NAT2 to be detected
immunohistochemically in adult mouse tissues (Stanley
et al., 1997) and traced during development (Stanley et al.,
1998). Like its human counterpart, mouse NAT2 is found in
early embryos in embryonic stem (ES) cells (Payton et al.,
1999a). The Nat2 gene is expressed in the neonatal period
unlike the other mouse Nat genes (Mitchell et al., 1999),
again mirroring human NAT1. Studies of congenic mouse
strains had identified the region around the Nat loci in mice
as implicated in susceptibility to neural tube defects includ-
ing cleft lip and palate (Karolyi et al., 1990) and intriguingly,
mouse Nat2 is expressed in the developing neural tube
(Stanley et al., 1998; Cornish et al., 2003; Figure 7).
Knowledge of the genetic region around the mouse Nat
genes (Fakis et al., 2000) allowed creation of transgenic mice
to study development. Many attempts were made to overex-
press human NAT1 in mouse ES cells (Johnson, 2002; Sim
et al., 2003). No normal mice were produced overexpressing
human NAT1 following targeted insertion using a strong pro-
moter, although two mice with neural tube defects were
found as well as deformed embryos and evidence of resorp-
tion early in gestation (Sim et al., 2003). Random insertion of
human NAT1 in mouse ES cells under the same strong pro-
moter generated several mice overexpressing human NAT1
(Cao et al., 2005) but at a much lower level than expected.
Overexpression of human NAT1 appears detrimental during
development confirming a role for mouse Nat2 in teratogen-
induced cleft lip and palate (Erickson et al., 2008; Erickson,
2010 for review). These studies mirror the link of human
NAT1 *10 genotype to neural tube defects (Lammer et al.,
2004; Jensen et al., 2005; 2006) but as discussed, the link
between this allele and increased NAT1 activity, although
attractive, is controversial.
It has been reasoned that excess human NAT1/mouse
NAT2 is detrimental in mice during development due to
increased folate catabolism driven by metabolism of the
folate breakdown product p-abaglu (Wakefield et al., 2007a;
Cao et al., 2010). These studies have been challenged recently
but additional information linking human NAT1 and mouse
NAT2 with folate has been described. These enzymes, but no
other NATs tested, are specifically able to catalyse hydrolysis
of acetyl CoA in the presence of folate (Rodrigues-Lima et al.,
2011). Hydrolysis of acetyl CoA in all NATs tested is acceler-
ated in the presence of an arylamine or hydrazine substrate –
the basis of NAT assays (Brooke et al., 2003a). Folate itself is
not a substrate for human NAT1 acetylation and these studies
open up the possibility that human NAT1 and its homologue
in mouse, Nat2, regulate homeostasis between acetyl CoA
and folate pools. A direct link remains to be established but
the observation explains why folate has been described as an
inhibitor of human NAT1 (Ward et al., 1995) since it serves to
deplete the cofactor acetyl CoA.
BJP E Sim et al.
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Knockout mice
Transgenic mice with mouse Nat2 deleted (Sugamori et al.,
2003) or interrupted by insertion of lacZ in frame with the
gene have been made (Cornish et al., 2003). The latter strain
of mice allows lacZ expression under control of the mouse
Nat promoter. Expression of mouse Nat2 can therefore be
studied by staining whole embryos with the β-galactosidase
substrate X-gal. This is illustrated dramatically in the skin of
mice (Figure 7) and adds further support to the similarity
with human NAT1, which is also found in skin. Mouse Nat2
is expressed in embryos including in the developing heart in
scattered clusters of cells including at the sino-atrial node
(Wakefield et al., 2005; 2008b). The detection of Nat2 expres-
sion in ES cells (Payton et al., 1999a) raises the question of
whether it is cardiac stem cells, which are expressing Nat2.
The expression of mouse Nat1 appears to be mainly restricted
to liver and gut and is unmodified in the Nat2 −/− mice
(Loehele et al., 2006).
Mice lacking Nat3 have been generated (Sugamori et al.,
2007) but show no differences in drug metabolism. Mice
lacking Nat1 and /or Nat2 appear healthy but show differ-
ences in drug metabolism (Sugamori et al., 2003) although
there appears to be defects that emerge in long-term breeding
programmes (Wakefield et al., 2007b). There appears to be a
gender imbalance in the offspring on breeding heterozygotes
(Cornish et al., 2003; Wakefield et al., 2008b). Gender differ-
ences in carcinogen activation have also been identified in
mice with the Nat2 gene deleted (Sugamori et al., 2012).
Mouse NAT2 is found in adult mice in a similar distribu-
tion to the human NAT1 (Stanley et al., 1997) including in
breast tissue (Williams et al., 2001; Wakefield et al., 2008b).
The relationship between human NAT1 expression and hor-
monal control (Adam et al., 2003; Butcher et al., 2007) and
the earlier studies on hormonal control of murine Nat
(Estrada-Rodgers et al., 1998) may well be a key to the gender-
linked asymmetry observed in transgenic mice and the
understanding of epigenetic control of gene expression are
areas of relative ignorance at present.
Structural studies
Early enzymology studies of Riddle and Jencks (1971) identi-
fied NAT activity involved formation of an acetylated enzyme
intermediate in a mechanism known as ping-pong bi-bi.
Cysteine was implicated in accepting the acetyl group from
acetyl CoA as NAT was inhibited by classic cysteine reactive
Figure 7
Generation of knockout mice. The Nat2 gene has been interrupted by a cassette in frame, which includes the β-galactosidase gene. Embryos can
be stained with X-gal, which is converted to a blue colour in the knockout mice. Ashows 12.5 day embryos with wild type, heterozygote
(Nat2+/−), a homozygote null (Nat2−/−). B shows 8.5 day whole mount embryo with wild type on the right and homozygote Nat2−/− on the
left. Staining in the developing neural tube is marked. Panel A is from Cornish et al., 2003. Panel B was prepared by L. Wakefield.
BJPNATs: JR Vane lecture 2012
British Journal of Pharmacology (2014) 171 2705–2725 2713
agents and by oxidative damage. One of us (ES) was particu-
larly interested to study the NAT enzymes from experience
gained with iron sulphur proteins (Sim and Vignais, 1979)
although NAT turned out not to be an iron sulphur protein.
Recent work has extended the oxidative sensitivity of the
NAT enzymes to reactive oxygen species (see Dupret et al.,
2005).
The sulphydryl reactive agents N-ethyl maleimide and
bromacetanilide inhibited NAT (Andres et al., 1988; Watson
et al., 1990) and it was clear from accumulated evidence (see
Weber and Hein, 1985) that NAT had an active site cysteine
residue. Identifying Cys69 as the active site inNAT from S. typh-
imurium (Watanabe et al., 1992) was followed by confirmation
through site-directed mutagenesis that the equivalent residue
in human NAT2 was Cys68 (Dupret and Grant, 1992).
The 3D structure of the NAT enzymes needed sufficient
pure protein for crystallization and recombinant protein was
the way forward. Following a well trodden path for drug-
metabolizing enzymes, sufficient pure stable recombinant
protein was obtained by cloning nat from S. typhimurium
(Sinclair et al., 1998) after many attempts to generate suffi-
cient human NAT as a recombinant enzyme for crystalliza-
tion (Ward et al., 1995; Sinclair and Sim, 1997). While the
yield of the S. typhimurium NAT was improved (Sinclair et al.,
1998), its substrate specificity and characteristics were estab-
lished (Figure 6). Labelling the active site cysteine with a
bromacetanilide conferring selectivity included a 13C label
and also 19F. The bromacetanilide binds covalently to the
active site Cys (determined by mass spectrometry) and we
hedged our bets with the possibility of probing the molecular
environment of the active site by 13C and 19F NMR should it
prove impossible to obtain crystals. It appeared we might
have needed the NMR approach as on one particular rare
occasion when there were diffractable crystals, the data col-
lected at the Daresbury Synchrotron was destroyed by an
electrical storm in transit to our Oxford computer. This was a
particularly low point but we eventually obtained diffraction
data with active S. typhimurium NAT labelled with selenom-
ethionine to allow the structure of the unique protein fold to
be solved (Sinclair et al., 2000).
When the structure was obtained, it was worth waiting for
(Figure 8). The active site Cys with its specificity label was
visible juxtaposed to a histidine residue and an aspartate
residue – a clearly identifiable catalytic triad, which activates
the Cys in order to allow the first step of catalysis in which
the Cys residue becomes acetylated before being transferred
to the incoming arylamine. The catalytic triad was obvious in
all NATs and appears essential for activity (Sandy et al.,
2005a): indeed in one of the NAT2 slow variants, the Asp of
the catalytic triad has been mutated to Asn and is inactive. In
all subsequent structures of NATs obtained, the catalytic triad
residues are superimposable.
Solving the protein fold allowed excellent work to be done
in solving the complete structure of mammalian NAT by NMR
(Zhang et al., 2006) and then the same bromacetanilide
approach was used (but without the 19F and 13C labels) in
studies from the Structural Genomics Consortium along with
site-directed mutagenesis to improve the stability of the
human NAT1 protein (Wu et al., 2007). The improvement in
stability of human NAT1 was based on comparing the sub-
strate specificity and stability of a series of chimeras of human
NAT1 and human NAT2 (Goodfellow et al., 2000). The impor-
tance of residues 125–127 were identified in a landmark study.
Comparison of the crystal structures of human NAT1 and
the model of human NAT2 rationalized the substrate speci-
ficity profiles of the two enzymes. Interestingly, modifying
only one residue in NAT1 (phenylalanine 125 to serine;
F125S) alters the specificity such that it resembles human
NAT2 in which residue 125 is serine. The same is true of the
mouse equivalent enzyme to human NAT1, Nat2, its speci-
ficity is altered when residue 125 is mutated from phenylala-
nine to serine (F125S) (Laurieri et al., 2010).
The NAT enzyme proteins, which are between 280 and
300 amino acids long (Sandy et al., 2005a; Vagena et al.,
2008), consist of three almost equivalently sized domains, an
α-domain; a β-domain and an α/β-C-terminal domain All
active site Cys, His107 and Asp122 residues are within the first
two domains and a third α-β lid folds over the active site. The
length and role of the third C-terminal domain differs most
among NATs. The C-terminus contributes to substrate recog-
nition because in human NAT1, removal of the third domain
results in a protein that hydrolyses acetyl CoA readily with no
arylamine substrate present (Sinclair and Sim, 1997). The
same is true of the enzyme from S. typhimurium (Mushtaq
et al., 2002) when either the entire third domain or even the
C-terminal 11 amino acids are missing. Thus, the interaction
with substrate and the interaction with cofactor can be sepa-
rated. Folate, which mediates hydrolysis specifically in
human NAT1 and mouse NAT2, may bind to effectively
unpeel the third domain of NAT from the active site. More
work is needed to confirm this interaction as there is no
Figure 8
Active site of S. typhimurium NAT. The residues forming the catalytic
triad are shown in pale yellow Cys69, His107 and Asp122. The active site
Cys69 has been labelled with bromacetanilide (bright green). The His
residue is behind the labelled Cys, and the Asp residue is in front. The
pale pink, green and blue residues correspond to the three domains
of the NAT structure.
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crystal structure with folate bound. New modelling data
support folate binding (Laurieri et al., 2014).
The role of the C-terminus also varies in relation to cofac-
tor binding. The structure of human NAT 1 with CoA bound
(Wu et al., 2007) and of an enzyme from Mycobacterium
marinum with CoA bound (Fullam et al., 2008) and from
Bacillus anthracis (Pluvinage et al., 2011) demonstrate that
CoA can bind in different positions in relation to the
C-terminus. Interestingly, the NAT enzyme from B. anthracis
was shown as having CoA bound although the recombinant
enzyme had been through several purification steps and had
not been incubated with CoA (Pluvinage et al., 2011).
NATs have been crystallized from many organisms and in
some cases with substrate bound including hydralazine
(Abuhammad et al., 2011) or isoniazid (Sandy et al., 2005b).
The ping-pong bi-bi mechanism implies that acetyl CoA
binds first but there is clear evidence from crystallography
and also from NMR (Delgoda et al., 2003; Kawamura et al.,
2008) studies that substrate can be bound without prior
binding of acetyl CoA.
NAT in bacteria
Finding NAT in bacteria prompted the question of whether
there might be a NAT homologue in mycobacteria to metabo-
lize the anti-tuberculosis agent isoniazid.
Isoniazid is a substrate of human NAT2 and isoniazid is a
prodrug activated by katG in M. tuberculosis. Using gridded
libraries from GlaxoSmithKline, we demonstrated that a nat
gene was present and expressed in both M. smegmatis and
M. tuberculosis (Payton et al., 1999b; 2001a,b). The genome of
M. tuberculosis was published around the same time (Cole
et al., 1998) and subsequent studies showed the gene in
M. bovis BCG and M. tuberculosis were identical (see Sim et al.,
2008b). The nat gene in mycobacteria is in a gene cluster,
which is essential for cholesterol catabolism for intracellular
fuel in these organisms (Van der Geize et al., 2007). The gene
cluster, including the nat gene, is essential for intracellular
survival of mycobacteria inside macrophage (Bhakta et al.,
2004; Anderton et al., 2006; Yam et al., 2009).
A subgroup of M. tuberculosis strains, which had an accu-
mulation of mutations, also had mutations in the nat gene,
which contributed marginally to isoniaizid resistance in clini-
cal isolates (Upton et al., 2001; Sholto-Douglas-Vernon et al.,
2005). Overexpressing nat experimentally in mycobacteria, it
was shown that NAT increases resistance to isoniazid (Payton
et al., 1999a; Bhakta et al., 2004) but is not the sole factor.
Making a nat gene deleted strain of M. bovis BCG, resulted in
an approximately threefold increase in sensitivity to isonia-
zid. These gene deletion studies however showed a very excit-
ing finding – that the nat deleted strain was defective in cell
wall synthesis as well as being essential for intracellular sur-
vival of M. bovis BCG (Bhakta et al., 2004). These studies
strongly suggested that the nat gene product from M. tuber-
culosis was a good drug target for anti-tuberculosis therapy.
We had extreme difficulty in generating large quantities
of the NAT from M. tuberculosis (TBNAT) as a recombinant
protein (Upton et al., 2001; Abuhammad et al., 2012) as did
others (Sikora et al., 2008). While we were improving the
yield of the TBNAT enzyme, we used NAT from M. smegmatis
(Sandy et al., 2005b) and then M. marinum (Fullam et al.,
2008), which is much closer in sequence to the NAT from
M. tuberculosis. M. marinum NAT is very soluble while the
M. tuberculosis NAT is not (Fullam et al., 2009; Abuhammad
et al., 2013 in press) and they show very different physical
properties (Lack et al., 2009), including melting at different
temperatures. The melting property resides in the first two
domains of the protein and may reflect the ability of TBNAT
to remain active in inflammatory conditions associated with
intracellular infection.
We have at last, after 15 years, obtained a crystal structure
of the NAT from M. tuberculosis by seeding a preparation of
M. tuberculosis NAT with a crystal of NAT from M. marinum
(Abuhammad et al., 2013). The substrate specificities of the
M. marinum and M. tuberculosis NAT enzymes are not identi-
cal and this illustrates the importance in drug discovery of
using an appropriate model or at least understanding the
differences when a surrogate has to be used. While
M. marinum NAT has been useful as a model, it emphasizes
the need to have the target protein available for developing
specific inhibitors (Fullam et al., 2009).
NAT as drug target
Development of NAT ligands. We embarked on a search for
specific NAT isoenzymes in 2003 to seek possible anti-
tuberculosis agents and coupled that with a search for human
NAT1 inhibitors. Up-regulation of human NAT1 in breast
cancer made the search for NAT inhibitors an attractive pros-
pect, which has recently been reinforced (Butcher and
Minchin, 2012). We were also interested in IBD because the
presence of NATs in the gut epithelium had been established
by immunohistochemistry (Hickman et al., 1998) and NAT is
involved in metabolic inactivation of the drug used to treat
IBD, namely 5-AS. Therefore, there might be a benefit in IBD
from co-administration of 5-AS and NAT inhibitors.
Screening for NAT inhibitors. An automatable assay was estab-
lished (Brooke et al., 2003a) which could be adapted to detect
inhibitors (Brooke et al., 2003b). A library of some 5000 com-
pounds was available (Russell et al., 2009) and we assembled
the other tools required – sufficient of all of the enzymes
we wished to use. We produced hundreds of milligrams of
each of human NAT1 (Wang et al., 2005), hamster NAT2
(Kawamura et al., 2004), S. typhimurium NAT (Sinclair et al.,
1998), M. smegmatis NAT (Sandy et al., 2002) and P. aeruginosa
NAT (Westwood et al., 2005). The mammalian enzymes were
to allow any possible toxicity to be identified early but gen-
erated very interesting results.
We compared the substrate specificity profiles of each of
these enzymes (Westwood et al., 2006) (Figure 6) and other
NATs used in later stages of sophistication in the screen,
which were available in lower quantities (Kawamura et al.,
2004; 2008; Fullam et al., 2009). The screen (Westwood et al.,
2011) identified compounds inhibiting either the eukaryotic
enzymes or the prokaryotic enzymes specifically (Figure 7).
All hits from the screen were resynthesized as in one case the
isomer in the screen had been incorrectly annotated (Fullam
et al., 2011).
Inhibitors and their development as potential antituberculars.
Following duplicate screening, compounds inhibiting
prokaryotic NAT enzymes specifically with an IC50 value of
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less than 10 μMwere tested for inhibition of growth of myco-
bacteria and of Escherichia coli. Of those that initially looked
interesting (Fullam et al., 2008; 2013; Westwood et al., 2010;
Abuhammad et al., 2012), we have studied two of these
classes in detail with structure activity analyses, identifying
the mechanism of inhibition.
In the triazole class, which shows competitive inhibition
with substrate, structure activity relationship (SAR) analysis
of anti-mycobacterial activity and NAT inhibition are coinci-
dent and modelling of binding to the active site of TBNAT
readily explains the SAR (Westwood et al., 2010). The effects
of the triazole class on M. bovis BCG phenotype was very
similar to that of deleting the nat gene (Bhakta et al., 2004),
including inhibiting growth of M. bovis BCG inside mac-
rophage without showing cytotoxicity for the macrophage.
Based on these findings, a commercial company, now known
as Summit plc, used a similar screening mechanism and gen-
erated compounds that were developed to the point of out-
licencing as anti-tuberculosis leads.
The piperidinols have recently been shown to bind cova-
lently, effectively acting in a prodrug-type manner (Figure 9).
Covalent binding is a feature of excellent drugs for tubercu-
losis including the recently identified benzothiazines (Batt
et al., 2012) as well as isoniazid, the front line prodrug. The
piperidinol class was our most effective hit in inhibiting
growth of M. tuberculosis and was equally effective at blocking
growth of M. tuberculosis in which the nat gene is deleted
(Abuhammad et al., 2012). This is now seen as a benefit as
polypharmacy (as it is called) is a feature of many excellent
and long-surviving drugs such as aspirin. It is good to see the
demise of the dogma that a lead compound was only worth
investigating if it could be demonstrated to be against
only one identifiable target. A broader minded attitude is
beginning to allow a flourishing pipeline for novel anti-
tuberculosis agents (http://www.tballiance.org/). In view of
the ever present possibility of the development of resistance,
it is important that all promising targets are pursued as well as
the return to the whole cell approach. Our own work has now
begun to focus on another of the gene products of the ‘nat’
gene cluster in M. tuberculosis, namely, HsaD (Lack et al.,
2009).
We have also looked at the effects of plant extracts and
found a terpenoid from the traditional medicine, the pepper
bark tree (Warburgia salutaris), which appears to act through
inhibition of NAT from mycobacteria. However, the extract
was not very potent (Madikane et al., 2007).
Inhibitors and their development for use in cancer. Of the com-
pounds identified as specific for eukaryotic NATs, we
rescreened to identify those which inhibited human NAT1
and its homologues from other mammals. We pursued only
two classes of compound that were effective at inhibiting
human NAT1 in breast cancer cell extracts (Russell et al.,
2009). One of the compounds was found to be generally
cytotoxic, a rhodanine (Russell et al., 2009), but it has been
exploited as a potential chemotherapeutic class (Tiang et al.,
2010; see Butcher and Minchin, 2012). The Australian group
are pushing forward with this approach and have also iden-
tified NAT as a breast cancer target using siRNA (Tiang et al.,
2011). Using low MW inhibitors has proved difficult as a
result of solubility issues.
In our own studies, a group of human NAT1-specific com-
pounds, naphthoquinones, have proved very interesting.
These compounds specifically change colour on binding to
human NAT1 and to the mouse homologue mouse Nat2. The
change of colour is due to a proton transfer between the
protein and the compound and site-directed mutagenesis
studies have allowed identification of the protein residues
involved (Laurieri et al., 2010; 2013). This compound shows
the same colour change with mouse NAT2 but not with any
of the other NAT enzymes. To use this for detecting human
NAT1 as a biomarker sensitivity will need to be improved and
we are currently making fluorescent versions of the naphtho-
quinone (Egleton, 2012).
Inhibitors of NAT and potential in IBD. 5-AS is used to treat
IBD and it was reasoned that if the acetylation of 5-AS could
be inhibited then this provides a method for improving the
amount of p-AS, which has be generated in the treatment of
IBD. 5-AS is metabolized by N-acetylation and while NATs in
gut bacteria are very good at acetylating 5-AS (Delomenie
et al., 2001; Westwood et al., 2006), the human enzyme
human NAT1 as well as NAT2 also acetylate 5-AS.
As 5-AS is mostly given as a prodrug, balsalazide or sul-
phasalazine, with 5-AS released by azoreductase in the gut
flora, it was necessary to understand whether potential NAT
inhibitors would also inhibit the gut flora azoreductases. We
commenced work on azoreductases during the sabbatical
leave of the corresponding author in Dundee with Mike
Coughtrie in 2005. Following bioinformatic analysis, we
made recombinant azoreductases from P. aeruginosa, which
are very soluble flavoproteins and crystallize readily (Wang
et al., 2007). Structures of azoreductase with balasalazide
bound show clearly that the relative position of the substrate
in relation to the isoalloxazine ring nitrogen atoms relies on
a proton relay system within the substrate resulting in the
reduction of the diazo bond in balsalazide (Ryan et al.,
2010a). We have also demonstrated that the antibiotic nitro-
furazone is reduced by azoreducatse with the electron flow
through the substrate from the flavin initially reducing the
nitroso group (Ryan et al., 2011; Figure 10).
It was proposed (Ryan et al., 2010b) that the azoreduc-
tases would reduce quinones and we found in separate
experiments that the naphthoquinone inhibitor of human
NAT1 was indeed an inhibitor of azoreductase. To expand
the diversity of NAT1 inhibitors, we have used the 3D shape
of our best inhibitor, the naphthoquinone, to screen against
shapes of all purchasable chemical space – some 35 million
compounds. From a random selection of 23 compounds
from the top 100 hits, almost half (10 compounds) had an
IC50 of less than 10 μM (Ballester et al., 2010). Although none
was better than the probe compound, the diversity of chemi-
cal classes made this a positive approach to diversification in
ligand identification.
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Figure 9
Inhibition of mycobacterial NAT by piperidinol. (A) The piperidinol inhibitor shows specificity for prokaryotic enzymes. (B) The mechanism of the
reaction for the piperidinol inhibitor to NAT is through a chemical transformation to the corresponding phenyl vinyl ketone (PVK), which then
binds to the active site Cys residue. C shows the inhibitor bound to the active site Cys residue. Electron density is shown around another Cys, which
has no such modification.
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Figure 10
Binding of substrates to azoreductase paAzoR1 from Pseudomonas aeruginosa. (A) Balsalazide (from Ryan et al., 2010a) structure was solved to
2.3 Å. Balsalazide is shown in purple and FMN cofactor is shown in yellow. (B) Nitrofurazone (Ryan et al., 2011). Structure was solved at 2.08 Å.
Nitrofurazone is in brown while stably bound water molecule involved in reduction is a black ball. C shows the tautomerization and charge relay
leading to reduction of the nitro group.
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